Company Eli Lilly and Company Sao Paulo

Company Eli Lilly and Company Sao Paulo

LILY34

BRLILYBDR006

Pharmaceuticals

Analysts' Consensus

Equities

LILY34

BRLILYBDR006

Pharmaceuticals

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Group companies

Sector

Sales per region

Ratings for Eli Lilly and Company

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Group companies

Sector

Sales per region

Ratings for Eli Lilly and Company

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals

Delayed Sao Paulo Other stock markets 10:26:31 26/06/2024 pm IST			5-day change	1st Jan Change
166.4 ^BRL	+1.17%		+0.33%	+78.27%

25/06	Top Midday Stories: Microsoft Hit with EU Antitrust Charges; Judge Blocks Swipe-Fee Settlement Between Visa, Mastercard and Retailers; Novo Nordisk Secures Chinese Approval for Weight-Loss Drug; Tesla, Ford Issue Recalls	MT
25/06	Eli Lilly Working With OpenAI to Develop Medicines Against Drug-Resistant Pathogens	DJ

Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:

- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;

- oncology (19.5%);

- immunology diseases (11.1%);

- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;

- other (3.3%).

Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).

Number of employees: 43,000

USD in Million	2022	Weight	2023	Weight	Delta
Human Pharmaceutical Products 100.0 %	28,541	100.0 %	34,124	100.0 %	+19.56%

USD in Million	2022	Weight	2023	Weight	Delta
United States 63.9 %	18,190	63.7 %	21,791	63.9 %	+19.80%
Europe 18.1 %	4,299	15.1 %	6,175	18.1 %	+43.62%
Other Foreign Countries 8.6 %	2,852	10.0 %	2,946	8.6 %	+3.30%
Japan 4.9 %	1,747	6.1 %	1,673	4.9 %	-4.28%
China 4.5 %	1,453	5.1 %	1,540	4.5 %	+5.98%

Managers	Title	Age	Since
David Ricks CEO	Chief Executive Officer	56	01/96/01
Ruth Gimeno PSD	President	-	-
David Hyman CTO	Chief Tech/Sci/R&D Officer	-	16/23/16
Alonzo Weems CMP	Compliance Officer	-	01/97/01
Daniel Skovronsky CTO	Chief Tech/Sci/R&D Officer	50	01/18/01
Diogo Rau CTO	Chief Tech/Sci/R&D Officer	-	17/21/17
Johna Norton PRN	Corporate Officer/Principal	57	01/17/01
Edgardo Hernandez PRN	Corporate Officer/Principal	-	01/05/01
Ilya Yuffa PRN	Corporate Officer/Principal	49	-
Ronald DeMattos		-	-

Members of the board	Title	Age	Since
Gabrielle Greene-Sulzberger BRD	Director/Board Member	63	25/21/25
Ralph Alvarez BRD	Director/Board Member	68	01/09/01
Jon Fyrwald BRD	Director/Board Member	63	01/05/01
Juan Luciano BRD	Director/Board Member	62	01/16/01
William Kaelin BRD	Director/Board Member	66	04/12/04
David Ricks CEO	Chief Executive Officer	56	01/96/01
Jamere Jackson BRD	Director/Board Member	54	01/16/01
Katherine Baicker BRD	Director/Board Member	52	12/11/12
Marschall Runge BRD	Director/Board Member	69	01/13/01
Karen Walker BRD	Director/Board Member	62	01/18/01

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	950,770,386	948,828,662 ( 99.80 %)	365,000 ( 0.0384 %)	99.80 %

Name	Equities	%	Valuation
Lilly Endowment, Inc. 10.26 %	97,556,910	10.26 %	80 030 M R$
Vanguard Fiduciary Trust Co. 7.654 %	72,745,011	7.654 %	59 676 M R$
PNC Investments LLC 5.412 %	51,438,196	5.412 %	42 197 M R$
BlackRock Advisors LLC 5.288 %	50,259,761	5.288 %	41 230 M R$
STATE STREET CORPORATION 3.605 %	34,258,566	3.605 %	28 104 M R$
Fidelity Management & Research Co. LLC 3.584 %	34,063,734	3.584 %	27 944 M R$
Capital Research & Management Co. (World Investors) 2.582 %	24,536,055	2.582 %	20 128 M R$
PRIMECAP Management Co. 2.236 %	21,254,190	2.236 %	17 436 M R$
T. Rowe Price International Ltd. 2.169 %	20,613,061	2.169 %	16 910 M R$
JPMorgan Investment Management, Inc. 1.957 %	18,597,930	1.957 %	15 257 M R$

Name	Equities	%	Valuation
Caixa DTVM SA 0.001487 %	424,450	0.001487 %	12 M R$
Western Asset Management Company DTVM Ltda. 0.000702 %	200,279	0.000702 %	6 M R$
Safra Asset Management Ltda. 0.000207 %	59,000	0.000207 %	2 M R$
Bram Bradesco Asset Management S/A DTVM 0.000171 %	48,730	0.000171 %	1 M R$
Warren Brasil Gestão e Administração e Recursos Ltda. 0.000034 %	9,625	0.000034 %	267 167 R$
XP Allocation Asset Management Ltda. 0.000014 %	3,884	0.000014 %	107 811 R$
BTG Pactual WM Gestão de Recursos Ltda. 0.000000 %	137	0.000000 %	3 803 R$

Name	Equities	%	Valuation
IMMUNOCORE HOLDINGS PLC 6.25%	2,548,145	6.25%	124,808,142 $
DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. 6.83%	8,084,411	6.83%	44,026,813 $
PROQR THERAPEUTICS N.V. 16.37%	13,371,562	16.37%	26,074,546 $
FOGHORN THERAPEUTICS INC. 7.23%	4,000,000	7.23%	23,320,000 $
AC IMMUNE SA 3.64%	3,615,328	3.64%	16,811,275 $
MICROTECH MEDICAL (HANGZHOU) CO., LTD. 7.60%	21,776,804	7.60%	10,995,108 $
PRECISION BIOSCIENCES, INC. 1.81%	125,405	1.81%	1,617,725 $

Eli Lilly & Co.

Lilly Corporate Center

46285, Indianapolis

+317 276 2000

http://www.lilly.com

Name	Category and Sector
ELI Lilly & Company (India) Pvt Ltd. ELI Lilly & Company (India) Pvt Ltd. Pharmaceuticals: MajorHealth Technology ELI Lilly & Company (India) Pvt Ltd. manufactures and markets pharmaceutical products. The firm's products treat diabetes, gastric cancer, lung cancer, osteoporosis, rheumatoid arthritis, men's health and growth-hormone deficiency. The company was founded in 1993 and is headquartered in Gurgaon, India.	Pharmaceuticals: Major
Eli Lilly Services India Pvt Ltd. Eli Lilly Services India Pvt Ltd. Pharmaceuticals: MajorHealth Technology Part of Eli Lilly & Co., Eli Lilly Services India Pvt Ltd. is an Indian company that discovers, develops, manufactures and sells pharmaceutical products. The company is based in Bangalore, India and was founded in 2015.	Pharmaceuticals: Major
Eli Lilly Export SA (Switzerland) Eli Lilly Export SA (Switzerland) Medical DistributorsDistribution Services Part of Eli Lilly & Co., Eli Lilly Export SA is a pharmaceutical company based in Vernier, Switzerland. The Swiss company combines care with research to develop innovative solutions for a better life worldwide.	Medical Distributors
Kinsale Financial Services
Lilly Nederland Finance BV Lilly Nederland Finance BV Miscellaneous Commercial ServicesCommercial Services Part of Eli Lilly & Co., Lilly Nederland Finance BV leases non-financial intangible assets. The company is based in Utrecht, Netherlands.	Miscellaneous Commercial Services
Eli Lilly SA Eli Lilly SA Pharmaceuticals: MajorHealth Technology Part of Eli Lilly & Co., Eli Lilly SA is a Swiss company that manufactures medicines. The company is based in Vernier, Switzerland.	Pharmaceuticals: Major
Eli Lilly (Suisse) SA
Lilly Global Nederland Holdings BV Lilly Global Nederland Holdings BV Financial ConglomeratesFinance Part of Eli Lilly & Co., Lilly Global Nederland Holdings BV functions as an investment holding Dutch company. The company is based in Utrecht, Netherlands.	Financial Conglomerates
Eli Lilly Vostok SA
Lilly Ventures Fund I LLC Lilly Ventures Fund I LLC Investment ManagersFinance Lilly Ventures Fund I LLC seeks investment opportunities located in the North American and European regions. The fund targets companies operating in the fields of biotechnology, medical technology and healthcare IT. It provides financing for early stage capital requirements.	Investment Managers
Eli Lilly Kinsale Ltd. Eli Lilly Kinsale Ltd. Pharmaceuticals: OtherHealth Technology Eli Lilly Kinsale Ltd., part of Eli Lilly & Co., is a company headquartered in Kinsale, Ireland, that manufactures medicines.	Pharmaceuticals: Other
Eli Lilly Group Pension Trustees Ltd. Eli Lilly Group Pension Trustees Ltd. Financial ConglomeratesFinance Part of Eli Lilly & Co., Eli Lilly Group Pension Trustees Ltd. operates as a British dormant company. The company is based in Basingstroke, UK.	Financial Conglomerates

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

904.6 USD

Average target price

860.5 USD

Spread / Average Target

-4.87%

Consensus

Estimates Revisions

Company calendar

	1st Jan change	Capi.
NOVO NORDISK A/S	+44.25%	654B
JOHNSON & JOHNSON	-6.28%	354B
MERCK & CO., INC.	+21.98%	337B
ABBVIE INC.	+10.80%	302B
ASTRAZENECA PLC	+18.45%	247B
ROCHE HOLDING AG	+2.09%	229B
NOVARTIS AG	+13.03%	219B
AMGEN INC.	+9.08%	171B
PFIZER, INC.	-3.54%	159B

Other Pharmaceuticals

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals